Liver fibrosis arises when chronic injury from viral hepatitis, alcohol, fatty liver disease, or other insults pushes hepatic stellate cells into an activated, myofibroblast-like state. In their quiescent form, these cells store vitamin A and quietly regulate blood flow through the liver’s sinusoids. When activated, they proliferate, migrate, and deposit extracellular matrix faster than it can be degraded, gradually choking the organ’s architecture into the stiff, nodular tissue of cirrhosis. Despite decades of research, no approved therapy reverses established fibrosis; treatment has largely meant removing the underlying cause and hoping the liver’s own regenerative capacity keeps pace. Praziquantel had already shown hints of anti-fibrotic activity in experimental settings, but how a drug best known for paralyzing schistosome worms could calm scar-forming liver cells remained a mystery.

To crack that mystery, the research team, led by Zhongkui Lu and Guoying Zhang of Nanjing Integrated Traditional Chinese and Western Medicine Hospital affiliated with Nanjing University of Chinese Medicine, together with colleagues at Xuzhou Medical University and Jinling Hospital, assembled potential praziquantel targets from public pharmacological databases and cross-referenced them against genes implicated in liver fibrosis. The overlap yielded 137 candidate genes. Enrichment analyses of this set pointed toward pathways involving xenobiotic metabolism and neuroactive ligand-receptor interactions, a signature consistent with the drug’s known pharmacology but also hinting at receptor-mediated effects beyond simple parasite membrane disruption.

The next step was to find the critical nodes within this network. Using the STRING database to construct a protein-protein interaction map and Cytoscape to visualize and prune it, the researchers identified six hub genes at the center of the praziquantel-fibrosis intersection: EGFR, ALB, TP53, PTGS2, ESR1, and CYP3A4. These genes span a striking range of functions, from growth factor signaling and tumor suppression to drug metabolism and hormone reception. But which of them actually matters causally for fibrosis, rather than merely being correlated with it? To answer that question, the team turned to Mendelian randomization, a statistical technique that uses naturally occurring genetic variants as instruments to test whether an exposure, here the expression or function of a candidate gene, has a causal effect on an outcome.

The Mendelian randomization analysis delivered a clear verdict for one gene. ESR1, the estrogen receptor alpha gene, showed genetically supported evidence of a protective causal role against liver fibrosis. A colocalization analysis, which tests whether the same genetic variant drives both the gene signal and the disease association in a genomic region, nominated a specific variant, rs3020404, as a plausible functional basis for the link. In other words, the population genetics did not merely suggest that ESR1 expression tracks with fibrosis severity; it suggested that inherited differences in ESR1 activity genuinely shift fibrosis risk, making the receptor a credible therapeutic target rather than a bystander.

Genetic plausibility still needed a physical mechanism, and for that the researchers turned to molecular modeling. Molecular docking placed praziquantel within ESR1’s ligand-binding pocket, and molecular dynamics simulations confirmed that the drug-receptor complex remains stable over simulated time, with the small molecule maintaining consistent contacts with the receptor. The modeling cannot prove binding in a living cell on its own, but it established that praziquantel and ESR1 are chemically compatible partners, setting the stage for functional tests.

The most revealing layer of the study came from single-cell RNA sequencing of liver tissue. Analyzing the data with the Seurat framework, the researchers mapped ESR1 expression across the liver’s cellular ecosystem and found it broadly present, but with a telling pattern: quiescent hepatic stellate cells and a cytokine-producing stellate cell subset, dubbed cyHSCs, expressed significantly higher levels of ESR1 than activated myofibroblastic stellate cells, or myHSCs. The receptor that praziquantel appears to target is most abundant precisely in the cell states that fibrosis threatens to destroy or corrupt, suggesting the drug may act by reinforcing the quiescent, non-fibrogenic identity of these cells.

To probe what ESR1 actually does inside stellate cells, the team ran virtual knockout experiments using scTenifoldKnk, a computational method that predicts how silencing a gene rewires a single-cell gene regulatory network. Removing ESR1 in silico disrupted a network whose most prominent casualties included RXFP1, EGFLAM, and several mitochondrial genome components such as MT-CO1, MT-CO2, and MT-ND4L. Pathway analysis of the perturbed genes showed strong enrichment in oxidative phosphorylation and immune signaling, including T cell receptor signaling. The picture that emerges is of ESR1 as an orchestrator of mitochondrial metabolic homeostasis and immunoregulatory signaling in stellate cells; when it is lost, the cells’ energy metabolism falters and inflammatory programs gain ground, conditions that favor fibrogenic activation.

Computational predictions, however convincing, demand wet-lab confirmation, and the researchers provided it. Working with LX-2 cells, a widely used human hepatic stellate cell line, they silenced ESR1 and tested whether praziquantel could still exert its anti-fibrotic effects. It could not, at least not fully. The loss-of-function experiments confirmed that ESR1 is functionally required for the drug’s benefit, closing the loop between network prediction, genetic causality, structural modeling, and cellular mechanism. The authors propose that praziquantel activates ESR1, which in turn maintains a protective gene network preserving mitochondrial function and immune balance in stellate cells, thereby blocking their transition into collagen-secreting myofibroblasts.

The implications extend well beyond one drug and one receptor. Repurposing praziquantel, whose safety profile is established through mass administration programs across the tropics, could dramatically shorten the path to clinical testing for an anti-fibrotic indication compared with developing a novel molecule from scratch. More broadly, the study showcases an integrative strategy, combining network pharmacology, Mendelian randomization, colocalization, molecular dynamics, single-cell transcriptomics, virtual knockout, and in vitro validation, that can elevate a computational hypothesis to a mechanistically grounded candidate therapy. ESR1 modulation itself may prove a fruitful therapeutic direction independent of praziquantel, and the identification of rs3020404 as a candidate functional variant offers a genetic handle for stratifying patients most likely to benefit. Much work remains: the findings rest heavily on human cell lines and public datasets, and animal models and clinical trials will be needed to confirm that the mechanism operates in scarred livers in living patients. But the study reframes a familiar antiparasitic as a plausible antifibrotic and hands hepatology a genetically validated, druggable target at the heart of the stellate cell’s decision to scar or stay quiet.

Subject of Research: Network pharmacology and experimental validation identifying ESR1 as the target through which praziquantel alleviates liver fibrosis

Article Title: Praziquantel targeting ESR1 to alleviate liver fibrosis: a comprehensive network analysis insight

Article References: Lu, Z., Kong, D., He, F., Lv, H., Guo, Y., Xia, X., & Zhang, G. (2026). Praziquantel targeting ESR1 to alleviate liver fibrosis: a comprehensive network analysis insight. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08941-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08941-1

Keywords: praziquantel, liver fibrosis, ESR1, hepatic stellate cells, Mendelian randomization, molecular docking, single-cell RNA sequencing, drug repurposing, mitochondrial function, hepatology, gene regulatory network, LX-2 cells

The study, published in the Journal of Cellular and Molecular Medicine, is a bibliometric analysis covering two decades of scholarly output on autoimmune hepatitis, from 1 January 2004 to 31 December 2024. Rather than measuring molecules or treating patients, bibliometrics measures the flow of scientific communication itself: which countries publish, which institutions collaborate, which journals shape the field, which authors are most cited, and, crucially, which research topics are gaining or losing momentum over time. The authors searched the Web of Science Core Collection for English-language articles and reviews, completed screening on 19 April 2025, and then processed the resulting dataset using three widely respected tools: VOSviewer version 1.6.20 for network construction and visualization, CiteSpace version 6.4.R1 for detecting citation bursts and knowledge structures, and the R package bibliometrix for quantitative summaries of productivity and thematic evolution.

The scale of the underlying literature is striking. The analysis captured 6310 records involving 110 countries, 5717 institutions, 28,429 authors, and 1348 journals. Annual publication output rose markedly after 2020, a surge that reflects both growing clinical interest and the broader post-pandemic acceleration of immunology and hepatology research. The United States, China, the United Kingdom, and Japan emerged as the leading contributors to the field, and two institutions stood out as hubs of international collaboration: the Mayo Clinic in the United States and King’s College Hospital in London. In terms of journals, Liver International published the most records, while Hepatology, one of the field’s flagship outlets, ranked as the most frequently co-cited journal, a signal of how often researchers draw on its content when building new studies. Among individual scientists, Albert J. Czaja and Ansgar W. Lohse featured prominently in both authorship and citation analyses, confirming their status as reference points for the field.

The authors are careful to note an important caveat about these rankings: bibliometric prominence reflects research activity and network position, not necessarily methodological quality or clinical impact. A highly cited paper is one that other scientists engage with, whether they are confirming, extending, or challenging it. Productivity measures the volume of output, not the value of each contribution. This distinction matters because the real story of the analysis lies not in the league tables of countries and authors but in how the questions attracting scientific attention have shifted across the twenty-year window.

Earlier research on autoimmune hepatitis, the keyword and citation analyses show, was dominated by a well-established trio of concerns: diagnosis, immunosuppressive treatment, and liver transplantation. Those themes formed the backbone of the field’s first decades, matching the clinical priorities of an era when the main challenges were recognizing the disease, calming the immune assault with steroids and azathioprine, and transplanting patients whose livers had already failed. Recent burst and trend analyses, however, tell a different story. The fastest-growing and most attention-grabbing topics now include the gut microbiota, the gut–liver axis, biomarker discovery, immune regulation, multi-omics technologies, and computational approaches such as machine learning. In other words, the field is migrating from descriptive and treatment-oriented questions toward mechanistic and data-intensive ones.

The microbiome pivot is grounded in a growing body of human and animal evidence. In a clinical cohort study, Liwinski and colleagues identified reduced microbial diversity in patients with autoimmune hepatitis and a disease-specific decline in Bifidobacterium, a genus of bacteria often associated with gut health. Notably, lower abundance of these organisms was associated with failure to achieve remission, hinting that gut ecology may track with, and possibly influence, treatment response. Building on that theme, Zhang and colleagues reported increased intestinal permeability among patients, a leakiness of the gut barrier that could allow microbial products to cross into the portal circulation and provoke hepatic inflammation. In murine models, the same team showed that barrier dysfunction and bacterial translocation intensified liver inflammation linked to RIP3, a signaling protein involved in a form of inflammatory cell death, while antibiotic treatment attenuated the liver injury. Together, these studies sketch a plausible pathway from gut barrier failure to immune-mediated liver damage.

Yet the authors of the bibliometric analysis are deliberately cautious about how far this narrative can be pushed. Human associations and animal interventions, they stress, do not establish a causal gut mechanism in patients. Association studies cannot determine whether microbial changes drive the disease or merely accompany it, and findings from murine models of altered permeability and bacterial translocation may not translate cleanly to the complexity of human autoimmune hepatitis. What the current evidence does support, they argue, is further systematic investigation of host–microbe interactions, ideally through designs capable of testing causality rather than simply cataloging correlations.

A similarly tempered picture emerges for biomarker research, one of the field’s hottest emerging areas. A recent review catalogued candidate gene-expression, protein, metabolite, and immune-cell markers but emphasized that clinically useful predictors remain inadequately established. Primary studies have produced intriguing candidate signals: serum metabolite signatures associated with cirrhosis, whole-blood transcriptional differences and candidate fibrosis-linked genes, and differential protein abundance measured in a pediatric cohort. Each of these findings represents a lead worth pursuing, the analysis concludes, but none yet constitutes a validated clinical test that a physician could order to predict disease course or treatment response. The gap between discovery and clinical utility remains wide, and closing it will require independent replication in large, well-characterized cohorts.

The same caution applies to the wave of artificial intelligence and machine learning now reaching autoimmune hepatitis. One deep-learning analysis included 123 pretreatment liver biopsies, while an exploratory machine-learning model was built with 233 development patients and validated in a cohort of only 33 patients. These are small numbers by the standards of clinical prediction modeling, and the studies were conducted in single-center, retrospective settings. Limited cohort sizes and constrained designs reduce the transportability of such models to the diverse patient populations seen in real-world practice, where biopsy availability, staining protocols, and clinical data structures vary widely. The bibliometric authors frame these computational efforts as preliminary evidence, promising but unproven, rather than as tools ready for the clinic.

The study closes with a clear-eyed statement of what bibliometrics can and cannot do, and with a roadmap for the field. Publication counts, network centrality, and co-citation patterns measure scholarly communication; they cannot establish biological causality, diagnostic performance, or treatment effectiveness, and they should never serve as proxies for study quality or patient benefit. What the analysis does reveal is directional change: autoimmune hepatitis research is moving toward microbiome science, biomarker discovery, and computational modeling, but these priorities remain exploratory and demand coordinated validation. The authors call for multicenter prospective studies that integrate standardized clinical phenotypes, treatment exposure, histology, and outcomes with immunomic, microbiome, and multi-omics data, with sampling and analyses prespecified, candidate mechanisms and biomarkers validated independently, and experimental testing where appropriate. Shared standards, they argue, are the only reliable way to distinguish reproducible biology from transient research hotspots and to translate robust signals into tools that genuinely improve diagnosis and care for patients living with this stubborn immune-mediated liver disease.

Subject of Research: Bibliometric analysis of global autoimmune hepatitis research trends from 2004 to 2024

Article Title: Evolving Trends in Autoimmune Hepatitis Research: A Bibliometric Analysis From 2004 to 2024

Article References: Kong, Y., & Lin, Z. (2026). Evolving Trends in Autoimmune Hepatitis Research: A Bibliometric Analysis From 2004 to 2024. Journal of Cellular and Molecular Medicine, 30(17), Article e71348. https://doi.org/10.1111/jcmm.71348

Image Credits: AI Generated

DOI: 10.1111/jcmm.71348

Keywords: autoimmune hepatitis, bibliometrics, gut microbiota, gut–liver axis, biomarkers, multi-omics, machine learning, immunosuppression, Web of Science, VOSviewer, CiteSpace, hepatology